In addition to CFS and serum NSE biomarkers, many studies have aimed to validate a plasma biomarker for neuronal damage that could be used non-invasively to study neurological diseases in both acute and chronic models [39, 88, 89]. This evidence concerns the gene ENO2 and nervous system disorder.